{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,5,14]],"date-time":"2026-05-14T14:28:32Z","timestamp":1778768912594,"version":"3.51.4"},"reference-count":44,"publisher":"Springer Science and Business Media LLC","issue":"1","funder":[{"DOI":"10.13039\/501100001809","name":"National Natural Science Foundation of China","doi-asserted-by":"publisher","award":["81600312"],"award-info":[{"award-number":["81600312"]}],"id":[{"id":"10.13039\/501100001809","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["BMC Cardiovasc Disord"],"published-print":{"date-parts":[[2018,12]]},"DOI":"10.1186\/s12872-018-0780-x","type":"journal-article","created":{"date-parts":[[2018,3,2]],"date-time":"2018-03-02T07:08:05Z","timestamp":1519974485000},"update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":16,"title":["Percutaneous closure versus medical therapy for stroke with patent foramen Ovale: a systematic review and meta-analysis"],"prefix":"10.1186","volume":"18","author":[{"given":"Xin-Lin","family":"Zhang","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Li-Na","family":"Kang","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Lian","family":"Wang","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-5351-2630","authenticated-orcid":false,"given":"Biao","family":"Xu","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"297","published-online":{"date-parts":[[2018,3,2]]},"reference":[{"key":"780_CR1","doi-asserted-by":"publisher","first-page":"2065","DOI":"10.1056\/NEJMcp1503946","volume":"374","author":"JL Saver","year":"2016","unstructured":"Saver JL. Cryptogenic stroke. N Engl J Med. 2016;374:2065\u201374.","journal-title":"N Engl J Med"},{"key":"780_CR2","doi-asserted-by":"publisher","first-page":"15086","DOI":"10.1038\/nrdp.2015.86","volume":"2","author":"S Homma","year":"2016","unstructured":"Homma S, Mess\u00e9 SR, Rundek T, Sun YP, Franke J, Davidson K, Sievert H, Sacco RL, Di Tullio MR. Patent foramen ovale. Nat Rev Dis Primers. 2016;2:15086.","journal-title":"Nat Rev Dis Primers"},{"key":"780_CR3","doi-asserted-by":"publisher","first-page":"2349","DOI":"10.1161\/STROKEAHA.109.547828","volume":"40","author":"AA Alsheikh-Ali","year":"2009","unstructured":"Alsheikh-Ali AA, Thaler DE, Kent DM. Patent foramen ovale in cryptogenic stroke: incidental or pathogenic? Stroke. 2009;40:2349\u201355.","journal-title":"Stroke"},{"key":"780_CR4","doi-asserted-by":"publisher","first-page":"527","DOI":"10.1161\/CIRCRESAHA.116.308447","volume":"120","author":"S Yaghi","year":"2017","unstructured":"Yaghi S, Bernstein RA, Passman R, Okin PM, Furie KL. Cryptogenic stroke: research and practice. Circ Res. 2017;120:527\u201340.","journal-title":"Circ Res"},{"key":"780_CR5","doi-asserted-by":"publisher","first-page":"991","DOI":"10.1056\/NEJMoa1009639","volume":"366","author":"AJ Furlan","year":"2012","unstructured":"Furlan AJ, Reisman M, Massaro J, Mauri L, Adams H, Albers GW, et al. Closure or medical therapy for cryptogenic stroke with patent foramen ovale. N Engl J Med. 2012;366:991\u20139.","journal-title":"N Engl J Med"},{"key":"780_CR6","doi-asserted-by":"publisher","first-page":"1083","DOI":"10.1056\/NEJMoa1211716","volume":"368","author":"B Meier","year":"2013","unstructured":"Meier B, Kalesan B, Mattle HP, Khattab AA, Hildick-Smith D, Dudek D, et al. Percutaneous closure of patent foramen ovale in cryptogenic embolism. N Engl J Med. 2013;368:1083\u201391.","journal-title":"N Engl J Med"},{"key":"780_CR7","doi-asserted-by":"publisher","first-page":"1092","DOI":"10.1056\/NEJMoa1301440","volume":"368","author":"JD Carroll","year":"2013","unstructured":"Carroll JD, Saver JL, Thaler DE, Smalling RW, Berry S, MacDonald LA, Marks DS, Tirschwell DL. Closure of patent foramen ovale versus medical therapy after cryptogenic stroke. N Engl J Med. 2013;368:1092\u2013100.","journal-title":"N Engl J Med"},{"key":"780_CR8","doi-asserted-by":"publisher","first-page":"2640","DOI":"10.1161\/STROKEAHA.113.001773","volume":"44","author":"GD Kitsios","year":"2013","unstructured":"Kitsios GD, Thaler DE, Kent DM. Potentially large yet uncertain benefits: a meta-analysis of patent foramen ovale closure trials. Stroke. 2013;44:2640\u20133.","journal-title":"Stroke"},{"key":"780_CR9","doi-asserted-by":"publisher","unstructured":"Li J, Liu J, Liu M, Zhang S, Hao Z, Zhang J, Zhang C. Closure versus medical therapy for preventing recurrent stroke in patients with patent foramen ovale and a history of cryptogenic stroke or transient ischemic attack. Cochrane Database Syst Rev. 2015;(9):CD009938. \n                    https:\/\/doi.org\/10.1002\/14651858.CD009938.pub2\n                    \n                  .","DOI":"10.1002\/14651858.CD009938.pub2"},{"key":"780_CR10","doi-asserted-by":"publisher","first-page":"120","DOI":"10.1093\/eurheartj\/ehu292","volume":"36","author":"S Stortecky","year":"2015","unstructured":"Stortecky S, Da Costa BR, Mattle HP, Carroll J, Hornung M, Sievert H, et al. Percutaneous closure of patent foramen ovale in patients with cryptogenic embolism: a network meta-analysis. Eur Heart J. 2015;36:120\u20138.","journal-title":"Eur Heart J"},{"key":"780_CR11","doi-asserted-by":"publisher","first-page":"907","DOI":"10.1016\/j.jacc.2015.12.023","volume":"67","author":"DM Kent","year":"2016","unstructured":"Kent DM, Dahabreh IJ, Ruthazer R, Furlan AJ, Reisman M, Carroll JD, et al. Device closure of patent foramen ovale after stroke: pooled analysis of completed randomized trials. J Am Coll Cardiol. 2016;67:907\u201317.","journal-title":"J Am Coll Cardiol"},{"key":"780_CR12","doi-asserted-by":"publisher","first-page":"264","DOI":"10.7326\/0003-4819-151-4-200908180-00135","volume":"151","author":"D Moher","year":"2009","unstructured":"Moher D, Liberati A, Tetzlaff J, Altman DG. Preferred reporting items for systematic reviews and meta-analyses: the PRISMA statement. Ann Intern Med. 2009;151:264\u20139. W64","journal-title":"Ann Intern Med"},{"key":"780_CR13","unstructured":"Higgins JPT, Altman DG, Sterne JAC. Assessing risk of bias in included studies. In: Higgins JPT, Green S, eds. Cochrane Handbook for Systematic Reviews of Interventions. Version 5.1.0 [updated March 2011]. The Cochrane Collaboration; 2011. Accessed at \n                    http:\/\/handbook-5-1.cochrane.org\/\n                    \n                   on 5 Dec 2017."},{"key":"780_CR14","unstructured":"Wells GA, Shea B, O\u2019Connell D, Peterson J, Welch V, Losos M, et al. The Newcastle-Ottawa Scale (NOS) for assessing the quality of nonrandomised studies in meta-analyses. Ottawa, Ontario, Canada: Ottawa Hospital Research Institute; 2013. Accessed at \n                    www.ohri.ca\/programs\/clinical_epidemiology\/oxford.asp\n                    \n                   on 15 Dec 2015."},{"key":"780_CR15","first-page":"719","volume":"22","author":"N Mantel","year":"1959","unstructured":"Mantel N, Haenszel W. Statistical aspects of the analysis of data from retrospective studies of disease. J Natl Cancer Inst. 1959;22:719\u201348.","journal-title":"J Natl Cancer Inst"},{"key":"780_CR16","doi-asserted-by":"publisher","first-page":"557","DOI":"10.1136\/bmj.327.7414.557","volume":"327","author":"JP Higgins","year":"2003","unstructured":"Higgins JP, Thompson SG, Deeks JJ, Altman DG. Measuring inconsistency in meta-analyses. BMJ. 2003;327:557\u201360.","journal-title":"BMJ"},{"key":"780_CR17","doi-asserted-by":"publisher","first-page":"1351","DOI":"10.1002\/sim.1761","volume":"23","author":"MJ Sweeting","year":"2004","unstructured":"Sweeting MJ, Sutton AJ, Lambert PC. What to add to nothing? Use and avoidance of continuity corrections in meta-analysis of sparse data. Stat Med. 2004;23:1351\u201375.","journal-title":"Stat Med"},{"key":"780_CR18","doi-asserted-by":"publisher","first-page":"3","DOI":"10.1186\/1471-2288-2-3","volume":"2","author":"DG Altman","year":"2002","unstructured":"Altman DG, Deeks JJ. Meta-analysis, Simpson's paradox, and the number needed to treat. BMC Med Res Methodol. 2002;2:3.","journal-title":"BMC Med Res Methodol"},{"key":"780_CR19","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1186\/1471-2288-2-1","volume":"2","author":"CJ Cates","year":"2002","unstructured":"Cates CJ. Simpson's paradox and calculation of number needed to treat from meta-analysis. BMC Med Res Methodol. 2002;2:1.","journal-title":"BMC Med Res Methodol"},{"key":"780_CR20","doi-asserted-by":"publisher","first-page":"1022","DOI":"10.1056\/NEJMoa1610057","volume":"377","author":"JL Saver","year":"2017","unstructured":"Saver JL, Carroll JD, Thaler DE, Smalling RW, LA MD, Marks DS, Tirschwell DL. Long-term outcomes of patent foramen ovale closure or medical therapy after stroke. N Engl J Med. 2017;377:1022\u201332.","journal-title":"N Engl J Med"},{"key":"780_CR21","doi-asserted-by":"publisher","first-page":"1011","DOI":"10.1056\/NEJMoa1705915","volume":"377","author":"JL Mas","year":"2017","unstructured":"Mas JL, Derumeaux G, Guillon B, Massardier E, Hosseini H, Mechtouff L, et al. Patent foramen ovale closure or anticoagulation vs. antiplatelets after stroke. N Engl J Med. 2017;377:1011\u201321.","journal-title":"N Engl J Med"},{"key":"780_CR22","doi-asserted-by":"publisher","first-page":"1033","DOI":"10.1056\/NEJMoa1707404","volume":"377","author":"L S\u00f8ndergaard","year":"2017","unstructured":"S\u00f8ndergaard L, Kasner SE, Rhodes JF, Andersen G, Iversen HK, Nielsen-Kudsk JE, et al. Patent foramen ovale closure or antiplatelet therapy for cryptogenic stroke. N Engl J Med. 2017;377:1033\u201342.","journal-title":"N Engl J Med"},{"key":"780_CR23","doi-asserted-by":"publisher","first-page":"803","DOI":"10.1161\/CIRCULATIONAHA.111.030494","volume":"125","author":"A Wahl","year":"2012","unstructured":"Wahl A, J\u00fcni P, Mono ML, Kalesan B, Praz F, Geister L, et al. Long-term propensity score-matched comparison of percutaneous closure of patent foramen ovale with medical treatment after paradoxical embolism. Circulation. 2012;125:803\u201312.","journal-title":"Circulation"},{"key":"780_CR24","doi-asserted-by":"publisher","first-page":"761","DOI":"10.2459\/JCM.0000000000000138","volume":"15","author":"B Alushi","year":"2014","unstructured":"Alushi B, Biasco L, Orzan F, Omed\u00e9 P, Sciuto F, Moretti C, et al. Patent foramen ovale treatment strategy: an Italian large prospective study. J Cardiovasc Med. 2014;15:761\u20138.","journal-title":"J Cardiovasc Med"},{"key":"780_CR25","doi-asserted-by":"crossref","unstructured":"Pezzini A, Grassi M, Lodigiani C, Patella R, Gandolfo C, Zini A, et al. Propensity score-based analysis of percutaneous closure versus medical therapy in patients with cryptogenic stroke and patent foramen ovale: the IPSYS registry (Italian project on stroke in young adults). Circ Cardiovasc Interv. 2016;9","DOI":"10.1161\/CIRCINTERVENTIONS.115.003470"},{"key":"780_CR26","doi-asserted-by":"publisher","first-page":"621","DOI":"10.3349\/ymj.2016.57.3.621","volume":"57","author":"J Moon","year":"2016","unstructured":"Moon J, Kang WC, Kim S, Oh PC, Park YM, Chung WJ, et al. Comparison of outcomes after device closure and medication alone in patients with patent foramen Ovale and cryptogenic stroke in Korean population. Yonsei Med J. 2016;57:621\u20135.","journal-title":"Yonsei Med J"},{"key":"780_CR27","doi-asserted-by":"publisher","first-page":"741","DOI":"10.1002\/ccd.20868","volume":"68","author":"BV Thanopoulos","year":"2006","unstructured":"Thanopoulos BV, Dardas PD, Karanasios E, Mezilis N. Transcatheter closure versus medical therapy of patent foramen ovale and cryptogenic stroke. Catheter Cardiovasc Interv. 2006;68:741\u20136.","journal-title":"Catheter Cardiovasc Interv"},{"key":"780_CR28","doi-asserted-by":"publisher","first-page":"74","DOI":"10.1017\/S0317167100005825","volume":"34","author":"L Casaubon","year":"2007","unstructured":"Casaubon L, McLaughlin P, Webb G, Yeo E, Merker D, Jaigobin C. Recurrent stroke\/TIA in cryptogenic stroke patients with patent foramen ovale. Can J Neurol Sci. 2007;34:74\u201380.","journal-title":"Can J Neurol Sci"},{"key":"780_CR29","doi-asserted-by":"publisher","first-page":"47","DOI":"10.1016\/j.ijcard.2010.10.032","volume":"156","author":"P Faggiano","year":"2012","unstructured":"Faggiano P, Frattini S, Piovesana P, Lorusso R, Chiari E, Scolari F, Padovani A, Cas LD. Low cerebrovascular event rate in subjects with patent foramen ovale and different clinical presentations: results from a prospective non randomized study on a population including patients with and without patent foramen ovale closure. Int J Cardiol. 2012;156:47\u201352.","journal-title":"Int J Cardiol"},{"key":"780_CR30","doi-asserted-by":"publisher","first-page":"39","DOI":"10.1017\/S0317167100004674","volume":"33","author":"JU Harrer","year":"2006","unstructured":"Harrer JU, Wessels T, Franke A, Lucas S, Berlit P, Klotzsch C. Stroke recurrence and its prevention in patients with patent foramen ovale. Can J Neurol Sci. 2006;33:39\u201347.","journal-title":"Can J Neurol Sci"},{"key":"780_CR31","doi-asserted-by":"publisher","first-page":"260","DOI":"10.1007\/s00415-012-6629-9","volume":"260","author":"S Horner","year":"2013","unstructured":"Horner S, Niederkorn K, Gattringer T, Furtner M, Topakian R, Lang W, Maier R, Gamillscheg A, Fazekas F. Management of right-to-left shunt in cryptogenic cerebrovascular disease: results from the observational Austrian paradoxical cerebral embolism trial (TACET) registry. J Neurol. 2013;260:260\u20137.","journal-title":"J Neurol"},{"key":"780_CR32","doi-asserted-by":"publisher","unstructured":"Kim M, Kim S, Moon J, Oh PC, Park YM, Shin DH, et al. Effect of patent foramen ovale closure for prevention on recurrent stroke or transient ischemic attack in selected patients with cryptogenic stroke. J Interv Cardiol. 2017. \n                    https:\/\/doi.org\/10.1111\/joic.12430\n                    \n                  .","DOI":"10.1111\/joic.12430"},{"key":"780_CR33","doi-asserted-by":"publisher","first-page":"129","DOI":"10.1016\/j.amjcard.2010.02.025","volume":"106","author":"JY Lee","year":"2010","unstructured":"Lee JY, Song JK, Song JM, Kang DH, Yun SC, Kang DW, Kwon SU, Kim JS. Association between anatomic features of atrial septal abnormalities obtained by omni-plane transesophageal echocardiography and stroke recurrence in cryptogenic stroke patients with patent foramen ovale. Am J Cardiol. 2010;106:129\u201334.","journal-title":"Am J Cardiol"},{"key":"780_CR34","doi-asserted-by":"publisher","first-page":"327","DOI":"10.1017\/S1047951112000029","volume":"22","author":"S Mazzucco","year":"2012","unstructured":"Mazzucco S, Bovi P, Carletti M, Tomelleri G, Golia G, Stegagno C, et al. A model of multi-disciplinary approach to the diagnosis and treatment of young patients with cryptogenic stroke and patent foramen ovale. Cardiol Young. 2012;22:327\u201334.","journal-title":"Cardiol Young"},{"key":"780_CR35","doi-asserted-by":"publisher","first-page":"293","DOI":"10.1016\/j.ijcard.2015.05.088","volume":"195","author":"N Mirzada","year":"2015","unstructured":"Mirzada N, Ladenvall P, Hansson PO, Eriksson P, Dellborg M. Recurrent stroke in patients with patent foramen ovale: an observational prospective study of percutaneous closure of PFO versus non-closure. Int J Cardiol. 2015;195:293\u20139.","journal-title":"Int J Cardiol"},{"key":"780_CR36","doi-asserted-by":"publisher","first-page":"109","DOI":"10.1159\/000321334","volume":"31","author":"M Paciaroni","year":"2011","unstructured":"Paciaroni M, Agnelli G, Bertolini A, Pezzini A, Padovani A, Caso V, et al. Risk of recurrent cerebrovascular events in patients with cryptogenic stroke or transient ischemic attack and patent foramen ovale: the FORI (foramen Ovale Registro Italiano) study. Cerebrovasc Dis. 2011;31:109\u201316.","journal-title":"Cerebrovasc Dis"},{"key":"780_CR37","doi-asserted-by":"publisher","first-page":"77","DOI":"10.1016\/j.ijcard.2004.03.005","volume":"101","author":"HW Schuchlenz","year":"2005","unstructured":"Schuchlenz HW, Weihs W, Berghold A, Lechner A, Schmidt R. Secondary prevention after cryptogenic cerebrovascular events in patients with patent foramen ovale. Int J Cardiol. 2005;101:77\u201382.","journal-title":"Int J Cardiol"},{"key":"780_CR38","doi-asserted-by":"publisher","first-page":"525","DOI":"10.1016\/j.jacc.2013.02.091","volume":"62","author":"R Marfella","year":"2013","unstructured":"Marfella R, Sasso FC, Siniscalchi M, Cirillo M, Paolisso P, Sardu C, et al. Brief episodes of silent atrial fibrillation predict clinical vascular brain disease in type 2 diabetic patients. J Am Coll Cardiol. 2013;62:525\u201330.","journal-title":"J Am Coll Cardiol"},{"key":"780_CR39","doi-asserted-by":"publisher","first-page":"88","DOI":"10.1016\/j.jdiacomp.2014.09.002","volume":"29","author":"MR Rizzo","year":"2015","unstructured":"Rizzo MR, Sasso FC, Marfella R, Siniscalchi M, Paolisso P, Carbonara O, et al. Autonomic dysfunction is associated with brief episodes of atrial fibrillation in type 2 diabetes. J Diabetes Complicat. 2015;29:88\u201392.","journal-title":"J Diabetes Complicat"},{"key":"780_CR40","doi-asserted-by":"publisher","first-page":"89","DOI":"10.1212\/WNL.0b013e3181aa2a19","volume":"73","author":"MA Almekhlafi","year":"2009","unstructured":"Almekhlafi MA, Wilton SB, Rabi DM, Ghali WA, Lorenzetti DL, Hill MD. Recurrent cerebral ischemia in medically treated patent foramen ovale: a meta-analysis. Neurology. 2009;73:89\u201397.","journal-title":"Neurology"},{"key":"780_CR41","doi-asserted-by":"publisher","first-page":"2381","DOI":"10.1093\/eurheartj\/ehv252","volume":"36","author":"DM Kent","year":"2015","unstructured":"Kent DM, Dahabreh IJ, Ruthazer R, Furlan AJ, Weimar C, Serena J, et al. Anticoagulant vs. antiplatelet therapy in patients with cryptogenic stroke and patent foramen ovale: an individual participant data meta-analysis. Eur Heart J. 2015;36:2381\u20139.","journal-title":"Eur Heart J"},{"key":"780_CR42","unstructured":"Neale T. Rivaroxaban trial in patients with embolic stroke of undetermined source stopped early. Available at \n                    https:\/\/www.tctmd.com\/news\/rivaroxaban-trial-patients-embolic-stroke-undetermined-source-stopped-early\n                    \n                  . Accessed 10 Oct 2017."},{"key":"780_CR43","doi-asserted-by":"publisher","first-page":"815","DOI":"10.1212\/WNL.0000000000002961","volume":"87","author":"SR Messe","year":"2016","unstructured":"Messe SR, Gronseth G, Kent DM, Kizer JR, Homma S, Rosterman L, Kasner SE. Practice advisory: recurrent stroke with patent foramen ovale (update of practice parameter): report of the guideline development, dissemination, and implementation Subcommittee of the American Academy of neurology. Neurology. 2016;87:815\u201321.","journal-title":"Neurology"},{"key":"780_CR44","doi-asserted-by":"publisher","first-page":"2160","DOI":"10.1161\/STR.0000000000000024","volume":"45","author":"WN Kernan","year":"2014","unstructured":"Kernan WN, Ovbiagele B, Black HR, Bravata DM, Chimowitz MI, Ezekowitz MD, et al. Guidelines for the prevention of stroke in patients with stroke and transient ischemic attack: a guideline for healthcare professionals from the American Heart Association\/American Stroke Association. Stroke. 2014;45:2160\u2013236.","journal-title":"Stroke"}],"container-title":["BMC Cardiovascular Disorders"],"original-title":[],"language":"en","link":[{"URL":"http:\/\/link.springer.com\/content\/pdf\/10.1186\/s12872-018-0780-x.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2019,3,1]],"date-time":"2019-03-01T19:23:41Z","timestamp":1551468221000},"score":1,"resource":{"primary":{"URL":"https:\/\/bmccardiovascdisord.biomedcentral.com\/articles\/10.1186\/s12872-018-0780-x"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2018,3,2]]},"references-count":44,"journal-issue":{"issue":"1","published-print":{"date-parts":[[2018,12]]}},"alternative-id":["780"],"URL":"https:\/\/doi.org\/10.1186\/s12872-018-0780-x","relation":{},"ISSN":["1471-2261"],"issn-type":[{"value":"1471-2261","type":"electronic"}],"subject":[],"published":{"date-parts":[[2018,3,2]]},"assertion":[{"value":"22 January 2018","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"22 February 2018","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"2 March 2018","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"Not applicable.","order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Ethics approval and consent to participate"}},{"value":"Not applicable.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Consent for publication"}},{"value":"The authors declare that they have no competing interests.","order":3,"name":"Ethics","group":{"name":"EthicsHeading","label":"Competing interests"}},{"value":"Springer Nature remains neutral with regard to jurisdictional claims in published maps and institutional affiliations.","order":4,"name":"Ethics","group":{"name":"EthicsHeading","label":"Publisher\u2019s Note"}}],"article-number":"45"}}